Iovance Biotherapeutics's total assets for Q3 2025 were $904.95M, a decrease of -0.27% from the previous quarter. IOVA total liabilities were $202.66M for the fiscal quarter, a -3.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.